Compass Pathways has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI), tracking the performance of NASDAQ biotechnology/pharmaceutical companies.
Compass Pathways has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI), tracking the performance of NASDAQ biotechnology/pharmaceutical companies.
Awakn Life Sciences reports its Q3 for fiscal 2021. Highlights include key IP and clinic acquisitions, and the company's first revenues.
MindMed's Phase IIa clinical trial of LSD for adults ADHD is officially underway, enrolling patients.
Cybin Inc receives its Notice of Allowance from the USPTO with respect to its patent for CYB004.
MindMed announces that interim CEO Robert Barrow has now been named the permanent CEO, and added as a Director.
atai partner, Recognify Life Sciences, reports positive Phase 2a results in treating Cognitive Impairment Associated with Schizophrenia.
Compass Pathways announces parallel treatment results with COMP360 for patients continuing to take SSRI-based antidepressants.
Numinus reports strong revenue growth, a gross profit on Q4 clinic operations, and cash position of CAD$59.2 million.
MindMed announces successful discussions with the FDA involving its MindMed Session Monitoring System device for clinical use.
Mydecine raises CAD$.5.5 million via convertible debenture and provided a corporate update, including news on its future Phase 2/3 smoking cessation trial.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now